INmune Bio's INKmune Shows Positive Efficacy In Multiple Cancer Cell Lines

INmune Bio Inc (NASDAQ:INMB) has announced solid tumor data in multiple cancer lines resistant to NK killing that can be overcome with the administration of INKmune.
The Tumor Microenvironment (TME) interaction with cancer cells and immune cells can drive tumor progression and prevent many cell therapies from being effective.
INKmune converts the patient's normal resting NK (rNK) cells into potent memory-like NK cells that target solid tumors directly, even in the presence of immunosuppressive immunoregulatory cells and hypoxia associated with the TME.
Related: INmune Bio Stock Jumps On Promising Biomarker Data From Early-Stage Blood Cancer Trial.
The company's preclinical data show that INKmune primes NK cells from patients and healthy donors to lyse NK-resistant ovarian (CaOva), prostate (CaPros), renal (RCC), and nasopharyngeal (NPC) cancer cells.
Compared to rNK cells, which are normal NK cells from healthy donors or patients before treatment with INKmune, the INKmune-primed NK cells demonstrated an enhanced ability to kill these resistant tumor cell lines.
The company identified more than 1,500 proteins that are upregulated in NK cells following INKmune priming and subsequent analysis compared them to NK cells primed with a cytokine cocktail of IL-12, IL-15 and IL-18.
Price Action: INMB shares are up 5.43% at $7.30 on the last check Wednesday.